Boston Scientific Co. (NYSE:BSX) Shares Sold by First American Trust FSB

First American Trust FSB reduced its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 25.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,477 shares of the medical equipment provider's stock after selling 36,633 shares during the period. First American Trust FSB's holdings in Boston Scientific were worth $9,600,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of BSX. Advisors Asset Management Inc. lifted its position in shares of Boston Scientific by 21.3% in the third quarter. Advisors Asset Management Inc. now owns 24,060 shares of the medical equipment provider's stock valued at $2,016,000 after acquiring an additional 4,233 shares in the last quarter. Nwam LLC purchased a new position in Boston Scientific in the 3rd quarter valued at about $294,000. Great Valley Advisor Group Inc. lifted its holdings in Boston Scientific by 2.7% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 40,455 shares of the medical equipment provider's stock valued at $3,390,000 after purchasing an additional 1,074 shares in the last quarter. Kingsview Wealth Management LLC boosted its stake in shares of Boston Scientific by 5.0% during the 3rd quarter. Kingsview Wealth Management LLC now owns 5,970 shares of the medical equipment provider's stock worth $500,000 after purchasing an additional 282 shares during the last quarter. Finally, Swedbank AB grew its holdings in shares of Boston Scientific by 0.6% during the third quarter. Swedbank AB now owns 1,430,925 shares of the medical equipment provider's stock worth $119,912,000 after buying an additional 8,246 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In related news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock worth $14,319,269 over the last ninety days. Corporate insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BSX. Morgan Stanley raised their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Truist Financial lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Stifel Nicolaus increased their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Finally, Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $108.91.

Boston Scientific Stock Down 1.5 %

Boston Scientific stock traded down $1.51 during midday trading on Friday, hitting $99.29. 7,402,670 shares of the company were exchanged, compared to its average volume of 6,051,507. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The company's fifty day moving average price is $102.16 and its 200-day moving average price is $93.11. The company has a market cap of $146.86 billion, a PE ratio of 79.43, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.